Vedolizumab - Immunotherapy related colitis

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve vedolizumab for the treatment of immunotherapy related colitis after steroids and infliximab (1st line) have been ineffective.

Vedolizumab will be assigned a RED traffic light status on the Prescribing Advisory Database (PAD)

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”